Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD

Fig. 3

Mean change from baseline in FEV1 over time on Day 7 (mITT population). Error bars represent standard errors. BID Twice daily, FEV 1 Forced expiratory volume in 1 s, GP Glycopyrronium, MDI Metered dose inhaler, mITT Modified intent-to-treat, QID Four times daily

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us